Castle Biosciences (CSTL) Financials

$24.18 +0.44 (+1.85%)

Closing price 10/23/2025 04:00 PM Eastern

Extended Trading

$23.98 -0.20 (-0.83%)

As of 05:12 AM Eastern

Annual Income Statements for Castle Biosciences

This table shows Castle Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-69	-57	18
Consolidated Net Income / (Loss)	-67	-57	18
Net Income / (Loss) Continuing Operations	-67	-57	18
Total Pre-Tax Income	-69	-57	22
Total Operating Income	-73	-68	8.67
Total Gross Profit	105	175	272
Total Revenue	137	220	332
Operating Revenue	137	220	332
Total Cost of Revenue	32	45	60
Operating Cost of Revenue	32	45	60
Total Operating Expenses	178	243	263
Selling, General & Admin Expense	143	180	200
Research & Development Expense	45	54	52
Amortization Expense	8.27	9.01	11
Other Special Charges / (Income)	-18	0.00	0.00
Total Other Income / (Expense), net	3.95	11	13
Interest Expense	0.02	0.01	0.58
Interest & Investment Income	3.97	11	13
Other Income / (Expense), net	0.00	0.00	0.56
Income Tax Expense	-1.77	0.10	3.32
Basic Earnings per Share	($2.58)	($2.14)	$0.66
Weighted Average Basic Shares Outstanding	26.05M	26.80M	27.78M
Diluted Earnings per Share	($2.58)	($2.14)	$0.62
Weighted Average Diluted Shares Outstanding	26.05M	26.80M	29.26M
Weighted Average Basic & Diluted Shares Outstanding	26.58M	27.45M	28.51M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00

This table shows Castle Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-20	-22	-29	-19	-6.87	-2.54	-2.53	8.92	2.27	9.59
Consolidated Net Income / (Loss)	-20	-21	-29	-19	-6.91	-2.58	-2.53	8.92	2.27	9.59
Net Income / (Loss) Continuing Operations	-20	-21	-29	-19	-6.91	-2.58	-2.53	8.92	2.27	9.59
Total Pre-Tax Income	-20	-21	-29	-19	-6.87	-2.54	-2.49	7.89	8.28	7.89
Total Operating Income	-22	-23	-32	-21	-9.64	-5.66	-5.47	5.01	5.08	4.05
Total Gross Profit	28	29	32	39	50	54	59	72	70	70
Total Revenue	37	38	42	50	61	66	73	87	86	86
Operating Revenue	37	38	42	50	61	66	73	87	86	86
Total Cost of Revenue	8.86	9.52	10	11	11	12	14	15	16	16
Operating Cost of Revenue	8.86	9.52	10	11	11	12	14	15	16	16
Total Operating Expenses	50	52	63	60	60	59	65	67	65	66
Selling, General & Admin Expense	37	38	47	45	45	44	48	51	50	50
Research & Development Expense	11	11	14	13	13	13	14	14	12	12
Amortization Expense	2.31	2.22	2.22	2.25	2.27	2.27	2.25	2.25	2.27	4.34
Total Other Income / (Expense), net	1.29	2.27	2.33	2.40	2.77	3.12	2.98	2.87	3.20	3.84
Interest Expense	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.27	0.20	0.09
Interest & Investment Income	1.29	2.28	2.34	2.40	2.77	3.12	3.00	3.14	3.40	3.37
Income Tax Expense	0.00	0.06	0.01	0.02	0.03	0.04	0.05	-1.03	6.01	-1.71
Basic Earnings per Share	($0.77)	($0.78)	($1.10)	($0.70)	($0.26)	($0.08)	($0.09)	$0.32	$0.08	$0.35
Weighted Average Basic Shares Outstanding	26.32M	26.05M	26.61M	26.73M	26.83M	26.80M	27.49M	27.65M	27.84M	27.78M
Diluted Earnings per Share	($0.77)	($0.78)	($1.10)	($0.70)	($0.26)	($0.08)	($0.09)	$0.31	$0.08	$0.32
Weighted Average Diluted Shares Outstanding	26.32M	26.05M	26.61M	26.73M	26.83M	26.80M	27.49M	28.74M	29.40M	29.26M
Weighted Average Basic & Diluted Shares Outstanding	26.35M	26.58M	26.69M	26.81M	26.91M	27.45M	27.61M	27.74M	28.01M	28.51M

This table details how cash moves in and out of Castle Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-207	-24	21
Net Cash From Operating Activities	-42	-5.63	65
Net Cash From Continuing Operating Activities	-42	-5.63	65
Net Income / (Loss) Continuing Operations	-67	-57	18
Consolidated Net Income / (Loss)	-67	-57	18
Depreciation Expense	11	12	16
Amortization Expense	-1.37	-5.49	-6.69
Non-Cash Adjustments To Reconcile Net Income	36	52	51
Changes in Operating Assets and Liabilities, net	-20	-6.60	-14
Net Cash From Investing Activities	-167	-16	-50
Net Cash From Continuing Investing Activities	-167	-16	-50
Purchase of Property, Plant & Equipment	-5.63	-14	-28
Acquisitions	-26	0.00	0.00
Purchase of Investments	-135	-189	-206
Sale of Property, Plant & Equipment	0.20	0.01	0.02
Sale and/or Maturity of Investments	0.00	187	184
Net Cash From Financing Activities	1.52	-2.30	6.14
Net Cash From Continuing Financing Activities	1.52	-2.30	6.14
Repayment of Debt	-0.12	-0.14	-0.10
Issuance of Debt	0.00	0.00	10
Issuance of Common Equity	2.49	2.71	2.98
Other Financing Activities, net	-0.86	-4.87	-6.75
Cash Interest Paid	0.02	0.01	0.43
Cash Income Taxes Paid	0.12	0.20	2.50

This table details how cash moves in and out of Castle Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-139	-11	-8.13	-19	-4.65	7.62	-16	2.62	9.39	25
Net Cash From Operating Activities	-5.22	-6.00	-25	-3.79	5.01	19	-6.84	24	23	24
Net Cash From Continuing Operating Activities	-5.22	-6.00	-25	-3.79	5.01	19	-6.84	24	23	24
Net Income / (Loss) Continuing Operations	-20	-21	-29	-19	-6.91	-2.58	-2.53	8.92	2.27	9.59
Consolidated Net Income / (Loss)	-20	-21	-29	-19	-6.91	-2.58	-2.53	8.92	2.27	9.59
Depreciation Expense	2.92	2.84	2.89	3.04	3.17	3.22	3.34	3.35	3.54	5.77
Amortization Expense	-0.18	-1.18	-1.23	-1.05	-1.57	-1.64	-1.70	-1.72	-1.65	-1.61
Non-Cash Adjustments To Reconcile Net Income	9.60	8.59	14	12	13	12	13	13	13	11
Changes in Operating Assets and Liabilities, net	2.69	4.37	-12	0.95	-2.68	7.10	-19	0.03	5.70	-0.64
Net Cash From Investing Activities	-134	-4.48	17	-15	-9.71	-7.67	-20	-21	-15	5.77
Net Cash From Continuing Investing Activities	-134	-4.48	17	-15	-9.71	-7.67	-20	-21	-15	5.77
Purchase of Property, Plant & Equipment	-2.04	-1.79	-3.34	-4.04	-2.46	-3.79	-9.15	-5.23	-6.38	-7.57
Purchase of Investments	-132	-2.88	-30	-56	-50	-52	-61	-52	-45	-47
Sale of Property, Plant & Equipment	0.00	0.19	0.01	0.00	0.00	0.00	0.01	0.00	0.00	0.01
Sale and/or Maturity of Investments	-	-	50	45	43	49	50	36	37	61
Net Cash From Financing Activities	0.39	-0.75	0.73	0.23	0.05	-3.30	11	0.04	0.84	-5.39
Net Cash From Continuing Financing Activities	0.39	-0.75	0.73	0.23	0.05	-3.30	11	0.04	0.84	-5.39
Repayment of Debt	-0.03	-0.03	-0.04	-0.04	-0.04	-0.04	-0.04	-0.01	-0.02	-0.03
Issuance of Common Equity	0.30	0.68	0.98	0.71	0.34	0.68	1.09	0.66	0.59	0.65
Other Financing Activities, net	0.12	-1.40	-0.22	-0.45	-0.26	-3.94	-0.41	-0.61	0.28	-6.01

This table presents Castle Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	447	453	531
Total Current Assets	292	296	360
Cash & Equivalents	123	99	120
Short-Term Investments	136	144	173
Accounts Receivable	23	38	51
Inventories, net	3.98	7.94	8.14
Prepaid Expenses	6.21	6.29	7.67
Plant, Property, & Equipment, net	14	25	51
Total Noncurrent Assets	141	132	120
Noncurrent Note & Lease Receivables	1.09	1.19	0.92
Goodwill	126	117	106
Other Noncurrent Operating Assets	13	14	13
Total Liabilities & Shareholders' Equity	447	453	531
Total Liabilities	48	62	75
Total Current Liabilities	36	48	49
Short-Term Debt	-	0.00	0.28
Accounts Payable	4.73	10	6.90
Accrued Expenses	5.26	7.32	7.99
Current Employee Benefit Liabilities	24	29	33
Other Current Liabilities	1.78	1.14	1.67
Total Noncurrent Liabilities	12	14	26
Long-Term Debt	-	0.00	9.75
Noncurrent Deferred & Payable Income Tax Liabilities	0.43	0.21	1.61
Other Noncurrent Operating Liabilities	12	14	15
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	399	391	456
Total Preferred & Common Equity	399	391	456
Preferred Stock	0.00	0.00	0.00
Total Common Equity	399	391	456
Common Stock	560	610	656
Retained Earnings	-161	-218	-200
Accumulated Other Comprehensive Income / (Loss)	-0.38	0.14	0.23

This table presents Castle Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	458	427	425	436	459	487	515
Total Current Assets	299	271	269	280	296	320	345
Cash & Equivalents	134	115	96	91	83	86	95
Short-Term Investments	132	117	130	139	156	174	185
Accounts Receivable	23	28	31	37	43	46	50
Inventories, net	3.80	4.52	6.12	5.77	7.65	8.01	6.57
Prepaid Expenses	6.80	6.80	6.11	7.10	6.22	6.72	8.15
Plant, Property, & Equipment, net	13	18	21	22	33	39	44
Total Noncurrent Assets	145	138	136	134	130	128	125
Noncurrent Note & Lease Receivables	1.19	1.22	1.23	1.34	1.06	1.13	1.11
Goodwill	130	124	122	120	115	113	111
Other Noncurrent Operating Assets	14	12	13	13	14	14	14
Total Liabilities & Shareholders' Equity	458	427	425	436	459	487	515
Total Liabilities	46	42	47	50	56	63	74
Total Current Liabilities	32	30	34	36	32	39	44
Accounts Payable	5.77	9.96	7.14	6.93	9.32	9.54	6.81
Accrued Expenses	5.11	5.61	7.32	5.90	6.74	7.45	8.07
Current Employee Benefit Liabilities	20	13	17	22	15	21	28
Other Current Liabilities	1.54	1.78	1.97	1.09	1.19	1.23	1.75
Total Noncurrent Liabilities	14	12	13	14	24	24	29
Long-Term Debt	-	-	-	-	10	10	10
Noncurrent Deferred & Payable Income Tax Liabilities	0.61	0.44	0.44	0.44	0.21	0.00	4.22
Other Noncurrent Operating Liabilities	14	11	12	13	14	14	15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	411	385	379	386	402	424	441
Total Preferred & Common Equity	411	385	379	386	402	424	441
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	411	385	379	386	402	424	441
Common Stock	552	575	588	602	623	636	650
Retained Earnings	-140	-190	-209	-216	-221	-212	-210
Accumulated Other Comprehensive Income / (Loss)	-0.19	-0.14	-0.14	-0.07	-0.11	-0.17	0.47

This table displays calculated financial ratios and metrics derived from Castle Biosciences' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	45.65%	60.38%	51.09%
EBITDA Growth	-73.65%	3.99%	130.32%
EBIT Growth	-81.78%	6.70%	113.57%
NOPAT Growth	-81.78%	6.70%	115.42%
Net Income Growth	-114.55%	14.41%	131.75%
EPS Growth	-108.06%	17.05%	128.97%
Operating Cash Flow Growth	-119.43%	86.49%	1,252.97%
Free Cash Flow Firm Growth	-4.88%	49.52%	68.82%
Invested Capital Growth	71.15%	5.44%	16.57%
Revenue Q/Q Growth	10.75%	14.47%	6.47%
EBITDA Q/Q Growth	-13.26%	21.86%	225.04%
EBIT Q/Q Growth	-11.75%	20.17%	988.73%
NOPAT Q/Q Growth	-11.75%	20.17%	1,395.68%
Net Income Q/Q Growth	-26.80%	23.89%	200.33%
EPS Q/Q Growth	-25.85%	24.65%	181.82%
Operating Cash Flow Q/Q Growth	-8.38%	81.38%	9.78%
Free Cash Flow Firm Q/Q Growth	23.24%	21.31%	-8.86%
Invested Capital Q/Q Growth	-3.39%	-5.04%	0.84%
Profitability Metrics	-	-	-
Gross Margin	76.64%	79.53%	81.87%
EBITDA Margin	-46.47%	-27.82%	5.58%
Operating Margin	-53.16%	-30.93%	2.61%
EBIT Margin	-53.16%	-30.93%	2.78%
Profit (Net Income) Margin	-48.99%	-26.15%	5.49%
Tax Burden Percent	97.44%	100.18%	84.61%
Interest Burden Percent	94.58%	84.39%	233.76%
Effective Tax Rate	0.00%	0.00%	15.39%
Return on Invested Capital (ROIC)	-45.81%	-32.96%	4.57%
ROIC Less NNEP Spread (ROIC-NNEP)	-40.33%	-29.03%	0.43%
Return on Net Nonoperating Assets (RNNOA)	29.26%	18.42%	-0.26%
Return on Equity (ROE)	-16.56%	-14.54%	4.31%
Cash Return on Invested Capital (CROIC)	-98.29%	-38.26%	-10.73%
Operating Return on Assets (OROA)	-16.01%	-15.09%	1.87%
Return on Assets (ROA)	-14.76%	-12.76%	3.71%
Return on Common Equity (ROCE)	-16.56%	-14.54%	4.31%
Return on Equity Simple (ROE_SIMPLE)	-16.82%	-14.69%	4.00%
Net Operating Profit after Tax (NOPAT)	-51	-48	7.34
NOPAT Margin	-37.21%	-21.65%	2.21%
Net Nonoperating Expense Percent (NNEP)	-5.49%	-3.94%	4.15%
Return On Investment Capital (ROIC_SIMPLE)	-12.78%	-12.16%	1.57%
Cost of Revenue to Revenue	23.36%	20.47%	18.13%
SG&A Expenses to Revenue	104.35%	81.97%	60.24%
R&D to Revenue	32.77%	24.40%	15.67%
Operating Expenses to Revenue	129.81%	110.46%	79.26%
Earnings before Interest and Taxes (EBIT)	-73	-68	9.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-64	-61	19
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.55	1.48	1.64
Price to Tangible Book Value (P/TBV)	2.27	2.12	2.14
Price to Revenue (P/Rev)	4.53	2.64	2.25
Price to Earnings (P/E)	0.00	0.00	40.91
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	2.44%
Enterprise Value to Invested Capital (EV/IC)	2.57	2.28	2.68
Enterprise Value to Revenue (EV/Rev)	2.64	1.54	1.40
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	24.99
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	50.22
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	63.16
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	7.14
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.02
Long-Term Debt to Equity	0.00	0.00	0.02
Financial Leverage	-0.73	-0.63	-0.62
Leverage Ratio	1.12	1.14	1.16
Compound Leverage Factor	1.06	0.96	2.72
Debt to Total Capital	0.00%	0.00%	2.15%
Short-Term Debt to Total Capital	0.00%	0.00%	0.06%
Long-Term Debt to Total Capital	0.00%	0.00%	2.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	97.85%
Debt to EBITDA	0.00	0.00	0.54
Net Debt to EBITDA	0.00	0.00	-15.27
Long-Term Debt to EBITDA	0.00	0.00	0.53
Debt to NOPAT	0.00	0.00	1.37
Net Debt to NOPAT	0.00	0.00	-38.59
Long-Term Debt to NOPAT	0.00	0.00	1.33
Altman Z-Score	7.68	5.59	6.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.09	6.20	7.29
Quick Ratio	7.81	5.90	6.97
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-109	-55	-17
Operating Cash Flow to CapEx	-766.14%	-41.34%	229.14%
Free Cash Flow to Firm to Interest Expense	-6,436.26	-5,020.81	-29.85
Operating Cash Flow to Interest Expense	-2,450.29	-511.45	112.42
Operating Cash Flow Less CapEx to Interest Expense	-2,770.12	-1,748.55	63.36
Efficiency Ratios	-	-	-
Asset Turnover	0.30	0.49	0.67
Accounts Receivable Turnover	6.72	7.12	7.42
Inventory Turnover	10.67	7.55	7.49
Fixed Asset Turnover	11.51	11.06	8.68
Accounts Payable Turnover	8.80	6.00	7.01
Days Sales Outstanding (DSO)	54.28	51.30	49.20
Days Inventory Outstanding (DIO)	34.21	48.37	48.73
Days Payable Outstanding (DPO)	41.49	60.85	52.04
Cash Conversion Cycle (CCC)	47.00	38.81	45.89
Capital & Investment Metrics	-	-	-
Invested Capital	141	148	173
Invested Capital Turnover	1.23	1.52	2.07
Increase / (Decrease) in Invested Capital	58	7.65	25
Enterprise Value (EV)	362	338	463
Market Capitalization	620	581	746
Book Value per Share	$15.15	$14.54	$16.28
Tangible Book Value per Share	$10.35	$10.18	$12.48
Total Capital	399	391	466
Total Debt	0.00	0.00	10
Total Long-Term Debt	0.00	0.00	9.75
Net Debt	-259	-243	-283
Capital Expenditures (CapEx)	5.44	14	28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.47	4.87	18
Debt-free Net Working Capital (DFNWC)	256	248	311
Net Working Capital (NWC)	256	248	311
Net Nonoperating Expense (NNE)	16	9.88	-11
Net Nonoperating Obligations (NNO)	-259	-243	-283
Total Depreciation and Amortization (D&A)	9.18	6.84	9.31
Debt-free, Cash-free Net Working Capital to Revenue	-1.80%	2.22%	5.39%
Debt-free Net Working Capital to Revenue	186.92%	112.82%	93.67%
Net Working Capital to Revenue	186.92%	112.82%	93.58%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.58)	($2.14)	$0.66
Adjusted Weighted Average Basic Shares Outstanding	26.05M	26.80M	27.78M
Adjusted Diluted Earnings per Share	($2.58)	($2.14)	$0.62
Adjusted Weighted Average Diluted Shares Outstanding	26.05M	26.80M	29.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.58M	27.45M	28.51M
Normalized Net Operating Profit after Tax (NOPAT)	-64	-48	7.34
Normalized NOPAT Margin	-46.56%	-21.65%	2.21%
Pre Tax Income Margin	-50.28%	-26.10%	6.49%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-4,285.59	-6,179.73	15.99
NOPAT to Interest Expense	-2,999.91	-4,325.81	12.71
EBIT Less CapEx to Interest Expense	-4,605.41	-7,416.82	-33.07
NOPAT Less CapEx to Interest Expense	-3,319.74	-5,562.90	-36.35
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Castle Biosciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	57.66%	53.11%	56.55%	43.92%	66.15%	72.47%	73.59%	73.53%	39.50%	30.54%
EBITDA Growth	-75.26%	-54.34%	-33.51%	-1,327.40%	57.25%	80.76%	87.17%	134.62%	186.75%	301.40%
EBIT Growth	-82.29%	-50.50%	-28.58%	-432.79%	55.24%	75.22%	82.64%	123.69%	152.69%	171.58%
NOPAT Growth	-82.29%	-50.50%	-28.58%	-432.79%	55.24%	75.22%	82.64%	138.28%	120.62%	224.37%
Net Income Growth	-71.73%	-220.65%	-18.60%	-1,039.38%	65.90%	87.49%	91.32%	147.50%	132.86%	471.71%
EPS Growth	-63.83%	-212.00%	-13.40%	-1,066.67%	66.23%	89.74%	91.82%	144.29%	130.77%	500.00%
Operating Cash Flow Growth	14.82%	-115.75%	-18.71%	57.94%	195.94%	409.78%	73.13%	733.86%	365.64%	31.09%
Free Cash Flow Firm Growth	-120.27%	14.37%	42.48%	81.12%	84.53%	84.40%	63.65%	21.93%	19.99%	-69.16%
Invested Capital Growth	199.68%	71.15%	40.24%	3.21%	7.27%	5.44%	13.17%	13.67%	9.78%	16.57%
Revenue Q/Q Growth	6.24%	3.59%	9.65%	19.27%	22.65%	7.52%	10.37%	19.22%	-1.40%	0.62%
EBITDA Q/Q Growth	-1,299.63%	-12.65%	-41.01%	35.80%	58.09%	49.30%	5.99%	273.29%	5.02%	17.72%
EBIT Q/Q Growth	-442.33%	-6.02%	-38.06%	32.88%	54.44%	41.31%	3.31%	191.61%	1.34%	-20.26%
NOPAT Q/Q Growth	-442.33%	-6.02%	-38.06%	32.88%	54.44%	41.31%	3.31%	248.03%	-75.46%	253.99%
Net Income Q/Q Growth	-1,128.70%	-1.82%	-41.64%	35.70%	63.23%	62.64%	1.78%	452.01%	-74.56%	322.65%
EPS Q/Q Growth	-1,183.33%	-1.30%	-41.03%	36.36%	62.86%	69.23%	-12.50%	444.44%	-74.19%	300.00%
Operating Cash Flow Q/Q Growth	41.96%	-14.85%	-323.98%	85.12%	232.38%	270.85%	-136.77%	451.10%	-2.75%	4.40%
Free Cash Flow Firm Q/Q Growth	-8.00%	33.57%	11.30%	70.34%	11.49%	33.02%	-106.66%	36.28%	9.29%	-41.61%
Invested Capital Q/Q Growth	-2.05%	-3.39%	8.94%	0.11%	1.81%	-5.04%	16.93%	0.56%	-1.68%	0.84%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.06%	75.17%	75.78%	77.94%	81.59%	81.21%	80.96%	83.31%	81.80%	81.25%
EBITDA Margin	-50.79%	-55.23%	-71.03%	-38.23%	-13.07%	-6.16%	-5.25%	7.63%	8.13%	9.51%
Operating Margin	-58.19%	-59.55%	-74.99%	-42.20%	-15.68%	-8.56%	-7.50%	5.76%	5.92%	4.69%
EBIT Margin	-58.19%	-59.55%	-74.99%	-42.20%	-15.68%	-8.56%	-7.50%	5.76%	5.92%	4.69%
Profit (Net Income) Margin	-54.71%	-53.78%	-69.47%	-37.45%	-11.23%	-3.90%	-3.47%	10.25%	2.65%	11.11%
Tax Burden Percent	100.00%	100.28%	100.05%	100.09%	100.47%	101.53%	101.81%	113.11%	27.40%	121.62%
Interest Burden Percent	94.02%	90.05%	92.60%	88.68%	71.30%	44.91%	45.49%	157.34%	163.06%	194.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-13.11%	72.60%	-21.62%
Return on Invested Capital (ROIC)	-51.96%	-51.32%	-60.93%	-32.80%	-13.98%	-9.12%	-8.06%	11.45%	3.09%	11.81%
ROIC Less NNEP Spread (ROIC-NNEP)	-50.32%	-49.75%	-58.19%	-31.21%	-13.91%	-9.67%	-8.63%	10.08%	2.74%	10.04%
Return on Net Nonoperating Assets (RNNOA)	38.46%	36.09%	38.69%	19.44%	8.65%	6.14%	5.05%	-5.97%	-1.66%	-6.24%
Return on Equity (ROE)	-13.50%	-15.23%	-22.25%	-13.36%	-5.33%	-2.98%	-3.01%	5.48%	1.44%	5.58%
Cash Return on Invested Capital (CROIC)	-146.97%	-98.29%	-76.13%	-48.18%	-46.56%	-38.26%	-30.34%	-19.53%	-9.67%	-10.73%
Operating Return on Assets (OROA)	-16.15%	-17.94%	-26.20%	-16.00%	-6.74%	-4.18%	-4.25%	3.63%	3.89%	3.17%
Return on Assets (ROA)	-15.19%	-16.20%	-24.27%	-14.20%	-4.82%	-1.90%	-1.97%	6.46%	1.74%	7.49%
Return on Common Equity (ROCE)	-13.50%	-15.23%	-22.25%	-13.36%	-5.33%	-2.98%	-3.01%	5.48%	1.44%	5.58%
Return on Equity Simple (ROE_SIMPLE)	-12.87%	0.00%	-18.62%	-23.46%	-19.57%	0.00%	-7.65%	-0.73%	1.38%	0.00%
Net Operating Profit after Tax (NOPAT)	-15	-16	-22	-15	-6.75	-3.96	-3.83	5.67	1.39	4.93
NOPAT Margin	-40.73%	-41.69%	-52.49%	-29.54%	-10.97%	-5.99%	-5.25%	6.52%	1.62%	5.71%
Net Nonoperating Expense Percent (NNEP)	-1.64%	-1.58%	-2.74%	-1.59%	-0.06%	0.55%	0.56%	1.37%	0.35%	1.77%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.00%	-	-	-	-1.01%	-	-	-	1.06%
Cost of Revenue to Revenue	23.94%	24.83%	24.22%	22.06%	18.41%	18.79%	19.04%	16.69%	18.20%	18.75%
SG&A Expenses to Revenue	98.96%	100.23%	111.24%	89.12%	72.56%	66.68%	66.46%	58.72%	58.87%	57.89%
R&D to Revenue	29.47%	29.50%	34.24%	26.54%	21.02%	19.65%	18.92%	16.25%	14.37%	13.64%
Operating Expenses to Revenue	134.25%	134.72%	150.76%	120.14%	97.27%	89.77%	88.46%	77.55%	75.88%	76.56%
Earnings before Interest and Taxes (EBIT)	-22	-23	-32	-21	-9.64	-5.66	-5.47	5.01	5.08	4.05
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-19	-21	-30	-19	-8.04	-4.07	-3.83	6.64	6.97	8.21
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.67	1.55	1.57	0.97	1.17	1.48	1.48	1.42	1.79	1.64
Price to Tangible Book Value (P/TBV)	2.44	2.27	2.31	1.43	1.70	2.12	2.07	1.93	2.39	2.14
Price to Revenue (P/Rev)	5.54	4.53	3.97	2.19	2.36	2.64	2.38	2.09	2.54	2.25
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	131.56	40.91
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.76%	2.44%
Enterprise Value to Invested Capital (EV/IC)	2.89	2.57	2.43	0.92	1.43	2.28	2.12	2.02	3.04	2.68
Enterprise Value to Revenue (EV/Rev)	3.39	2.64	2.44	0.84	1.16	1.54	1.46	1.22	1.67	1.40
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	91.40	24.99
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	50.22
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	63.16
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	28.27	8.62	8.82	7.14
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.02
Financial Leverage	-0.76	-0.73	-0.66	-0.62	-0.62	-0.63	-0.59	-0.59	-0.60	-0.62
Leverage Ratio	1.08	1.12	1.11	1.10	1.12	1.14	1.12	1.14	1.15	1.16
Compound Leverage Factor	1.02	1.01	1.03	0.98	0.80	0.51	0.51	1.79	1.87	2.26
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.42%	2.31%	2.22%	2.15%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.42%	2.31%	2.22%	2.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	97.58%	97.69%	97.78%	97.85%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.28	-1.08	1.76	0.54
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	6.53	26.84	-47.30	-15.27
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.28	-1.08	1.76	0.53
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.34	-0.91	-17.69	1.37
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	7.81	22.64	476.49	-38.59
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.34	-0.91	-17.69	1.33
Altman Z-Score	9.26	8.05	8.85	4.92	5.75	6.04	6.90	6.39	7.23	6.76
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.37	8.09	8.99	7.98	7.70	6.20	9.25	8.12	7.78	7.29
Quick Ratio	9.04	7.81	8.62	7.62	7.34	5.90	8.82	7.75	7.45	6.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-112	-74	-66	-20	-17	-12	-24	-15	-14	-20
Operating Cash Flow to CapEx	-256.46%	-374.77%	-763.25%	-93.90%	204.32%	490.42%	-74.72%	459.12%	366.14%	322.29%
Free Cash Flow to Firm to Interest Expense	-18,665.03	-18,600.10	-16,497.85	-6,525.30	-8,663.50	-5,802.80	-1,713.19	-56.61	-68.97	-213.39
Operating Cash Flow to Interest Expense	-870.67	-1,500.00	-6,359.75	-1,262.00	2,506.00	9,293.50	-488.21	88.88	116.11	264.84
Operating Cash Flow Less CapEx to Interest Expense	-1,210.17	-1,900.25	-7,193.00	-2,606.00	1,279.50	7,398.50	-1,141.57	69.52	84.40	182.66
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.30	0.35	0.38	0.43	0.49	0.57	0.63	0.66	0.67
Accounts Receivable Turnover	5.98	6.72	6.39	6.21	6.42	7.12	7.12	7.44	7.15	7.42
Inventory Turnover	8.77	10.67	10.55	8.35	8.79	7.55	8.01	7.38	9.15	7.49
Fixed Asset Turnover	11.29	11.51	11.02	10.56	10.87	11.06	9.80	9.72	9.36	8.68
Accounts Payable Turnover	6.35	8.80	5.46	7.61	6.63	6.00	5.05	6.26	8.22	7.01
Days Sales Outstanding (DSO)	61.01	54.28	57.11	58.74	56.88	51.30	51.26	49.05	51.06	49.20
Days Inventory Outstanding (DIO)	41.62	34.21	34.59	43.70	41.51	48.37	45.59	49.46	39.90	48.73
Days Payable Outstanding (DPO)	57.50	41.49	66.84	47.98	55.07	60.85	72.26	58.35	44.42	52.04
Cash Conversion Cycle (CCC)	45.13	47.00	24.86	54.46	43.32	38.81	24.60	40.16	46.54	45.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	145	141	153	153	156	148	173	174	171	173
Invested Capital Turnover	1.28	1.23	1.16	1.11	1.27	1.52	1.54	1.76	1.91	2.07
Increase / (Decrease) in Invested Capital	97	58	44	4.77	11	7.65	20	21	15	25
Enterprise Value (EV)	420	362	372	141	223	338	367	351	521	463
Market Capitalization	686	620	604	366	453	581	596	601	791	746
Book Value per Share	$15.65	$15.15	$14.49	$14.19	$14.39	$14.54	$14.64	$15.35	$15.90	$16.28
Tangible Book Value per Share	$10.69	$10.35	$9.82	$9.62	$9.93	$10.18	$10.46	$11.27	$11.92	$12.48
Total Capital	411	399	385	379	386	391	412	434	451	466
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	10	10	10	10
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	10	10	10	9.75
Net Debt	-266	-259	-232	-226	-230	-243	-229	-250	-270	-283
Capital Expenditures (CapEx)	2.04	1.60	3.33	4.03	2.45	3.79	9.15	5.23	6.37	7.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.49	-2.47	8.90	9.83	14	4.87	25	21	21	18
Debt-free Net Working Capital (DFNWC)	267	256	241	235	243	248	264	281	300	311
Net Working Capital (NWC)	267	256	241	235	243	248	264	281	300	311
Net Nonoperating Expense (NNE)	5.17	4.64	7.14	3.97	0.16	-1.38	-1.30	-3.25	-0.88	-4.66
Net Nonoperating Obligations (NNO)	-266	-259	-232	-226	-230	-243	-229	-250	-270	-283
Total Depreciation and Amortization (D&A)	2.74	1.66	1.66	1.99	1.61	1.58	1.64	1.63	1.89	4.16
Debt-free, Cash-free Net Working Capital to Revenue	1.20%	-1.80%	5.85%	5.87%	7.05%	2.22%	9.81%	7.39%	6.63%	5.39%
Debt-free Net Working Capital to Revenue	216.16%	186.92%	158.29%	140.48%	126.71%	112.82%	105.22%	97.69%	96.34%	93.67%
Net Working Capital to Revenue	216.16%	186.92%	158.29%	140.48%	126.71%	112.82%	105.22%	97.69%	96.34%	93.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.77)	($0.78)	($1.10)	($0.70)	($0.26)	($0.08)	($0.09)	$0.32	$0.08	$0.35
Adjusted Weighted Average Basic Shares Outstanding	26.32M	26.05M	26.61M	26.73M	26.83M	26.80M	27.49M	27.65M	27.84M	27.78M
Adjusted Diluted Earnings per Share	($0.77)	($0.78)	($1.10)	($0.70)	($0.26)	($0.08)	($0.09)	$0.31	$0.08	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	26.32M	26.05M	26.61M	26.73M	26.83M	26.80M	27.49M	28.74M	29.40M	29.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.35M	26.58M	26.69M	26.81M	26.91M	27.45M	27.61M	27.74M	28.01M	28.51M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-16	-22	-15	-6.75	-3.96	-3.83	3.51	3.56	2.84
Normalized NOPAT Margin	-41.02%	-42.24%	-52.49%	-29.54%	-10.97%	-5.99%	-5.25%	4.03%	4.14%	3.28%
Pre Tax Income Margin	-54.71%	-53.63%	-69.44%	-37.42%	-11.18%	-3.84%	-3.41%	9.06%	9.65%	9.14%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3,589.33	-5,708.00	-7,880.50	-7,052.33	-4,820.00	-2,829.00	-390.79	18.56	25.27	44.02
NOPAT to Interest Expense	-2,512.53	-3,995.60	-5,516.35	-4,936.63	-3,374.00	-1,980.30	-273.55	21.00	6.92	53.54
EBIT Less CapEx to Interest Expense	-3,928.83	-6,108.25	-8,713.75	-8,396.33	-6,046.50	-4,724.00	-1,044.14	-0.80	-6.44	-38.15
NOPAT Less CapEx to Interest Expense	-2,852.03	-4,395.85	-6,349.60	-6,280.63	-4,600.50	-3,875.30	-926.91	1.64	-24.79	-28.63
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Castle Biosciences (NASDAQ: CSTL) has shown a strong trend of revenue growth over the last two years. The operating revenue climbed from approximately $38.3 million in Q4 2022 to $86.3 million in Q4 2024, more than doubling. This indicates substantial top-line growth, reflecting successful commercialization or market expansion efforts.

Gross profit has followed this positive trajectory, increasing from around $28.8 million in Q4 2022 to about $70.1 million in Q4 2024, demonstrating improved profitability at the gross margin level driven by higher sales and controlled cost of revenue.

Net income has significantly improved, turning from losses to sustained profitability in 2024. For instance, in Q4 2022, the company reported a net loss of approximately $20.6 million, whereas in Q4 2024, it recorded net income of $9.6 million. This turnaround highlights operational improvements and effective cost management.

Operating expenses (SG&A and R&D) have increased year-over-year in absolute terms, reflecting investment in growth and product development. However, the rise in revenues has helped absorb these costs better, resulting in positive operating income in recent quarters, with operating income growing from a loss of $22.8 million in Q4 2022 to a positive $4.1 million in Q4 2024.

Cash flow from operations has recovered substantially, going from negative in early 2023 to a robust positive $24.4 million in Q4 2024, suggesting improving cash generation capacity and business sustainability.

Balance sheet metrics show increasing total assets and shareholders' equity, supporting growth capacity. Cash and equivalents plus short-term investments increased from about $269 million in Q2 2023 to approximately $344.8 million in Q3 2024, reflecting a strong liquidity position.

Consistent revenue growth, more than doubling from 2022 to 2024.
Turnaround from net losses to positive net income in recent quarters.
Improved gross profit margins aligned with revenue increases.
Positive and growing cash flow from operating activities as of 2024.
Strong liquidity position with growing cash, equivalents, and investments.
Increasing operating expenses, particularly SG&A and R&D, to support growth.
Stable long-term debt levels around $10 million, manageable in context of cash flows.
Shares outstanding have increased slightly, modest dilution observed.
Historical losses in 2022 and early 2023 indicating challenging initial profitability.
Negative net income and operating income reported through much of 2022 and early 2023.

Overall, Castle Biosciences has demonstrated significant revenue and profit growth over the past two years, with improving cash flow and a healthy balance sheet. While expenses have risen to support growth initiatives, the company has successfully transitioned from losses to profitability, which is a positive signal for investors looking at the stock's recent turnaround trajectory.

10/24/25 05:35 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Castle Biosciences' Financials

When does Castle Biosciences' fiscal year end?

According to the most recent income statement we have on file, Castle Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Castle Biosciences' net income changed over the last 2 years?

Castle Biosciences' net income appears to be on a downward trend, with a most recent value of $18.25 million in 2024, falling from -$67.14 million in 2022. The previous period was -$57.47 million in 2023. View Castle Biosciences' forecast to see where analysts expect Castle Biosciences to go next.

What is Castle Biosciences' operating income?

Castle Biosciences' total operating income in 2024 was $8.67 million, based on the following breakdown:

Total Gross Profit: $271.86 million
Total Operating Expenses: $263.19 million

How has Castle Biosciences' revenue changed over the last 2 years?

Over the last 2 years, Castle Biosciences' total revenue changed from $137.04 million in 2022 to $332.07 million in 2024, a change of 142.3%.

How much debt does Castle Biosciences have?

Castle Biosciences' total liabilities were at $75.40 million at the end of 2024, a 21.5% increase from 2023, and a 56.5% increase since 2022.

How much cash does Castle Biosciences have?

In the past 2 years, Castle Biosciences' cash and equivalents has ranged from $98.84 million in 2023 to $122.95 million in 2022, and is currently $119.71 million as of their latest financial filing in 2024.

How has Castle Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Castle Biosciences' book value per share changed from 15.15 in 2022 to 16.28 in 2024, a change of 7.5%.

Related Companies

This page (NASDAQ:CSTL) was last updated on 10/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Castle Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Financials

Annual Income Statements for Castle Biosciences

Quarterly Income Statements for Castle Biosciences

Annual Cash Flow Statements for Castle Biosciences

Quarterly Cash Flow Statements for Castle Biosciences

Annual Balance Sheets for Castle Biosciences

Quarterly Balance Sheets for Castle Biosciences

Annual Metrics And Ratios for Castle Biosciences

Quarterly Metrics And Ratios for Castle Biosciences

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Castle Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools